Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G/A for Amylyx Pharmaceuticals, Inc. Common Stock (AMLX).
- Disclosed ownership: 7.1%.
- Date of event: 31 Dec 2025.
BlackRock, Inc. - 31 Dec 2025 SCHEDULE 13G/A Report for Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- AMLX
- Shares outstanding
- 109,628,845 shares
- Disclosed Ownership
- 7,783,648 shares
- Ownership
- 7.1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 21 Jan 2026, 12:30:30 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 17 Jul 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 7.1% ownership in Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 17 Jul 2025.
- Current filing was accepted on 21 Jan 2026, 12:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 7.1% | 7,783,648 | 7,653,538 | 0 | Spencer Fleming | Managing Director |